Search results for "Response"

showing 10 items of 4136 documents

A human hepatocellular in vitro model to investigate steatosis

2006

The present study was designed to define an experimental model of hepatocellular steatosis with a fat overaccumulation profile in which the metabolic and cytotoxic/apoptotic effects could be separated. This was accomplished by defining the experimental conditions of lipid exposure that lead to significant intracellular fat accumulation in the absence of overt cytotoxicity, therefore allowing to differentiate between cytotoxic and apoptotic effects. Palmitic (C16:0) and oleic (Cl 8: 1) acids are the most abundant fatty acids (FFAs) in liver triglycerides in both normal subjects and patients with nonalcoholic fatty liver disease (NAFLD). Therefore, human hepatocytes and HepG2 cells were incub…

medicine.medical_specialtyHepG2Carcinoma HepatocellularCell SurvivalPalmitic AcidApoptosisBiologyFatty Acids NonesterifiedIn Vitro TechniquesToxicologyfatty acidscellular steatosisPalmitic acidchemistry.chemical_compoundInternal medicineCell Line TumorNonalcoholic fatty liver diseasemedicineHumansCytotoxicityDose-Response Relationship DrugapoptosisGeneral Medicinemedicine.diseaseFatty LiverDose–response relationshipmedicine.anatomical_structureEndocrinologychemistryBiochemistryApoptosisNeutral RedHepatocyteHepatocyteslipids (amino acids peptides and proteins)hepatocytesSteatosisIntracellularOleic Acid
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa…

2013

medicine.medical_specialtyHepatologyFibroTestbusiness.industryRibavirinIndependent predictorGastroenterologyPegylated interferon alfa-2bchemistry.chemical_compoundChronic hepatitischemistryVirologic responseInternal medicinemedicinebusinessJournal of Hepatology
researchProduct

A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin

2000

Background: Biologically derived porcine secretin has been used as a diagnostic agent in clinical gastrointestinal practice for many years. Pure synthetic porcine secretin is now available for investigational clinical use. Aim: To compare the pharmacology of synthetic porcine secretin and biologically derived porcine secretin in healthy volunteers. Methods: Secretin stimulation tests were performed in 12 volunteer subjects in a double-blind, randomized, Latin square crossover design study comparing three doses of synthetic porcine secretin (0.05, 0.2, and 0.4 μg/kg) with a standard dose of biologically derived porcine secretin (1 CU/kg). Duodenal aspirates were analysed for total volume and…

medicine.medical_specialtyHepatologybusiness.industryBicarbonateGastroenterologyPeptide hormonedigestive systemCrossover studydigestive system diseasesDose Response StudySecretinchemistry.chemical_compoundfluids and secretionsEndocrinologymedicine.anatomical_structurechemistryGastrointestinal hormoneInternal medicinemedicinePharmacology (medical)businessPancreasVolunteerhormones hormone substitutes and hormone antagonistsAlimentary Pharmacology & Therapeutics
researchProduct

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

2014

SummaryBackground A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). Aim To estimate the maximum-tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. Methods Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300–500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. Results Twenty-one patients were enrolled, inclu…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyPharmacokinetic analysisSurgeryPharmacokineticsInternal medicineHepatocellular carcinomaToxicitymedicineIdarubicinPharmacology (medical)Myocardial infarctionbusinessAdverse effectObjective responsemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Hypoosmolar conditions reduce extracellular volume fraction and enhance epileptiform activity in the CA3 region of the immature rat hippocampus

2006

The osmolarity of the extracellular space (ECS) compartment is an important factor determining the excitability of neuronal tissue. In the adult hippocampus an important role of osmolarity and ECS diffusion parameters on the susceptibility to epileptic events is well established, but the influence of hypo- and hyperosmolar conditions on the immature hippocampus remains elusive. To investigate the influence of osmolarity on epileptiform activity, extracellular field potentials were recorded in the CA3 region of hippocampal slices of immature (postnatal days 4-7) Wistar rats. The ECS diffusion parameters were determined by the real-time tetramethylammonium (TMA+) iontophoretic method with ion…

medicine.medical_specialtyHippocampusAlpha (ethology)In Vitro TechniquesHippocampal formationHippocampusCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicinePotassium Channel BlockersmedicineExtracellularAnimalsMagnesium4-AminopyridineRats WistarNeuronsOsmoleTetramethylammoniumEpilepsyDose-Response Relationship DrugOsmotic concentrationIontophoresisOsmolar ConcentrationRatsQuaternary Ammonium CompoundsEndocrinologyAnimals NewbornHypotonic SolutionschemistryExtracellular SpaceNeuroscienceJournal of Neuroscience Research
researchProduct

The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size

2001

Abstract Objectives: To disclose if oral estradiol (E 2 ), alone or in combination with natural progesterone (P) or medroxyprogesterone acetate (MPA), may modify the oxidizability of low density lipoprotein (LDL), and if the effect is achieved at physiological dosages. LDL oxidizability was assessed by the resistance to oxidation by copper and by the particle size profile, since small particles have increased oxidation susceptibility. Methods: Thirty-three women received two consecutive, two-month length doses of 1 and 2 mg/day of oral E 2 . They were then randomly assigned to a fourteen-day treatment of 2 mg/day E 2 plus either 300 mg/day P or 5 mg/day MPA. A parallel group of experiments …

medicine.medical_specialtyHormone Replacement Therapymedicine.drug_classMedroxyprogesteroneAdministration OralMedroxyprogesterone AcetateGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundHigh-density lipoproteinOral administrationInternal medicinemedicineHumansMedroxyprogesterone acetateParticle SizeProgesteroneDiminutionDose-Response Relationship DrugEstradiolbusiness.industryObstetrics and GynecologyCholesterol LDLMiddle AgedPostmenopauseEndocrinologychemistryEstrogenLow-density lipoproteinFemalelipids (amino acids peptides and proteins)businessOxidation-Reductionmedicine.drugLipoproteinMaturitas
researchProduct

Traps N' Clots: NET-Mediated Thrombosis and Related Diseases.

2020

medicine.medical_specialtyHypertension PulmonaryArterial Occlusive DiseasesGastroenterologyExtracellular TrapsAutoimmune DiseasesTranslational Research BiomedicalMiceInternal medicineNeoplasmsThromboembolismmedicineAnimalsHumansInflammationVenous Thrombosisbusiness.industryThrombosisHematologymedicine.diseasePlatelet ActivationThrombosisSystemic Inflammatory Response SyndromeEndothelium VascularbusinessForecastingThrombosis and haemostasis
researchProduct

Role of cytokines and oxidative stress in the pathophysiology of acute pancreatitis: therapeutical implications.

2002

Abstract Severe acute pancreatitis causes a high incidence of mortality due to the systemic inflammatory response syndrome leading to multiple organ failure. At present, there is no treatment against severe acute pancreatitis, other than supportive critical care. The relationship between pancreatic injury and the uncontrolled systemic response is not completely understood. Nevertheless, experimental and clinical evidences have shown that pro-inflammatory cytokines and oxidative stress are critically involved in the development of local and systemic complications associated with severe acute pancreatitis. Serum levels of pro-inflammatory cytokines, such as TNF-alpha and IL-1beta, increase du…

medicine.medical_specialtyImmunologyInflammationmedicine.disease_causePentoxifyllinechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyHumansXanthine oxidasePharmacologyInflammationbusiness.industryPneumoniamedicine.diseaseSystemic inflammatory response syndromeOxidative StressEndocrinologymedicine.anatomical_structurechemistryPancreatitisImmunologyAcute DiseaseAcute pancreatitisCytokinesPancreatic injurymedicine.symptombusinessPancreasOxidative stressmedicine.drugCurrent drug targets. Inflammation and allergy
researchProduct

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DA…

2016

Abstract Background: While first line therapy for FL with chemotherapy or chemoimmunotherapy produces durable responses, most patients (pts) with FL eventually relapse. Those who become resistant to chemoimmunotherapy have limited treatment options. Ibrutinib, an inhibitor of BTK (Bruton's tyrosine kinase) and ITK (interleukin-2-inducible T-cell kinase), has demonstrated robust clinical activity in various B-cell non-Hodgkin lymphomas. Previous Phase 1 and 2 studies have shown promising results with single-agent ibrutinib in pts with relapsed or refractory FL (Bartlett NL. Blood. 2014; 800 & Fowler N. Blood. 2015; 2706). The aim of the DAWN study was to provide additional efficacy and s…

medicine.medical_specialtyImmunologyPopulationFollicular lymphomaPhases of clinical researchBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChemoimmunotherapyPartial responseInternal medicinemedicineeducationeducation.field_of_studybusiness.industryCell BiologyHematologymedicine.diseaseRegimenchemistry030220 oncology & carcinogenesisIbrutinibImmunologybusinessProgressive disease030215 immunologyBlood
researchProduct